Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
101418-00-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Topical antiseptic and astringentacidic polycondensation polymer
Mechanism of action
A highly acidic polymeric compound that coagulates proteins in damaged or infected tissue and has local antimicrobial, haemostatic and astringent effects. It promotes demarcation and removal of devitalised tissue while supporting epithelial regeneration in selected formulations.
Indications / reported uses
Local treatment of selected vaginal and cervical infections and lesions, including bacterial vaginosis and cervical ectopy, where authorised.
Topical use in selected oral, dental and wound preparations is product-specific; the exact formulation and route determine the approved use.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Policresulen Environmental Risk Assessment (ERA) (the Policresulen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.